SCHEDULE 13G/A: Millennium Management Discloses Passive 0.6% Stake in Milestone Pharmaceuticals

Millennium Management LLC and its affiliates, including Integrated Core Strategies (US) LLC and Millennium Group Management LLC, along with Israel A. Englander, have disclosed a passive beneficial ownership of 0.6% in Milestone Pharmaceuticals Inc., totaling 322,082 common shares.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an Amendment No. 4 to Schedule 13G.
• The filing discloses beneficial ownership of 322,082 common shares of Milestone Pharmaceuticals Inc.
• This represents 0.6% of Milestone Pharmaceuticals Inc.'s outstanding common shares.
• The reporting persons hold shared voting and shared dispositive power over all 322,082 shares.
• The event requiring this filing occurred on March 31, 2025.
• The filing indicates that the securities were not acquired and are not held for the purpose of changing or influencing the control of Milestone Pharmaceuticals Inc.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of a passive ownership stake. It contains no positive or negative news regarding the issuer's operations, financial performance, or strategic direction.

Positives

• The disclosure indicates that a prominent institutional investor, Millennium Management, holds a stake in Milestone Pharmaceuticals Inc., which could be viewed as a vote of confidence, albeit for a small, passive position.

Negatives

• The filing itself, being a routine ownership disclosure, does not contain specific negative information regarding Milestone Pharmaceuticals Inc.'s operations or financial performance.

Risks

• This Schedule 13G filing is a disclosure of passive ownership and does not contain information about specific risks related to Milestone Pharmaceuticals Inc.'s business or operations.

Future Outlook

This document is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Milestone Pharmaceuticals Inc.'s future performance or outlook.

Industry Context

This filing is a routine disclosure of a passive investment stake by an institutional investor in a pharmaceutical company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that Milestone Pharmaceuticals Inc. is a publicly traded entity attracting institutional investment.

Related Party Transactions

• A Joint Filing Agreement, dated April 29, 2025, was executed by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, confirming their agreement to file the Schedule 13G jointly.

Stakeholder Impact

• Shareholders: The disclosure of a passive 0.6% stake by Millennium Management indicates institutional interest, but the small percentage is unlikely to have a significant direct impact on shareholder value or corporate strategy.
• Employees, Customers, Suppliers, Creditors: This ownership disclosure has no direct or immediate impact on these stakeholders as it does not relate to the company's operations, financial health, or strategic direction.

Key Dates

Keywords

Milestone Pharmaceuticals Inc., Millennium Management LLC, Integrated Core Strategies (US) LLC, Israel A. Englander, Schedule 13G, Beneficial Ownership, Common Shares, Passive Investment, SEC Filing